Cargando…
Construction of Curcumin and Paclitaxel Co-Loaded Lipid Nano Platform and Evaluation of Its Anti-Hepatoma Activity in vitro and Pharmacokinetics in vivo
PURPOSE: The present study aimed to construct a co-loading platform encapsulating curcumin and paclitaxel at ratios of 2:1–80:1 (w/w) designated “CU-PTX-LNP” and explored the synergistic effects of CU-PTX at different composite proportions on liver cancer cells using the combination index (CI) metho...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10135418/ https://www.ncbi.nlm.nih.gov/pubmed/37122500 http://dx.doi.org/10.2147/IJN.S399289 |
_version_ | 1785031972334075904 |
---|---|
author | Wei, Yuxun Wei, Yumeng Sheng, Lin Ma, Jingwen Su, Zhilian Wen, Jie Li, Lanmei Jia, Qiang Liu, Huiyang Si, Hui Xiong, Linjin Chen, Jinglin Cheng, Ju Zuo, Ying Yang, Hongru Zhao, Ling |
author_facet | Wei, Yuxun Wei, Yumeng Sheng, Lin Ma, Jingwen Su, Zhilian Wen, Jie Li, Lanmei Jia, Qiang Liu, Huiyang Si, Hui Xiong, Linjin Chen, Jinglin Cheng, Ju Zuo, Ying Yang, Hongru Zhao, Ling |
author_sort | Wei, Yuxun |
collection | PubMed |
description | PURPOSE: The present study aimed to construct a co-loading platform encapsulating curcumin and paclitaxel at ratios of 2:1–80:1 (w/w) designated “CU-PTX-LNP” and explored the synergistic effects of CU-PTX at different composite proportions on liver cancer cells using the combination index (CI) method. METHODS: The CU lipid nanoplatform (CU-LNP) formulation was optimized via single-factor and orthogonal experiments. Various concentrations of PTX were added to the optimal formulation of CU-LNP to generate CU-PTX-LNP and the nanoplatform characterized via differential scanning calorimetry (DSC), transmission electron microscope (TEM), X-ray diffraction (XRD), zeta potential, polydispersity index (PDI), and size analyses. The cumulative release, stability, and cytotoxicity of CU-PTX-LNP in LO2, HepG2, and SMMC-7221 cells were assessed in vitro, followed by safety investigation and pharmacokinetic studies in vivo. The anti-tumor activity of CU-PTX-LNP was also evaluated using nude mice. RESULTS: CU-PTX-LNP formulations containing CU:PTX at a range of proportions (2:1–80:1; w/w) appeared as uniformly dispersed nanosized spherical particles with high entrapment efficiency (EE> 90%), sustained release and long-lasting stability. Data from in vitro cytotoxicity assays showed a decrease in the IC(50) value of PTX of CU-PTX-LNP (by 5.47–332.7 times in HepG2 and 4.29–143.21 times in SMMC-7221 cells) compared to free PTX. In vivo, CU-PTX-LNP displayed excellent biosafety, significant anti-tumor benefits and enhanced pharmacokinetic behavior with longer mean residence time (MRT((0-t);) CU: 4.31-fold, PTX: 4.61-fold) and half-life (t(1/2z;) CU: 1.83-fold, PTX: 2.28-fold) relative to free drugs. CONCLUSION: The newly designed CU-PTX-LNP platform may serve as a viable technological support system for the successful production of CU-PTX composite preparations. |
format | Online Article Text |
id | pubmed-10135418 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-101354182023-04-28 Construction of Curcumin and Paclitaxel Co-Loaded Lipid Nano Platform and Evaluation of Its Anti-Hepatoma Activity in vitro and Pharmacokinetics in vivo Wei, Yuxun Wei, Yumeng Sheng, Lin Ma, Jingwen Su, Zhilian Wen, Jie Li, Lanmei Jia, Qiang Liu, Huiyang Si, Hui Xiong, Linjin Chen, Jinglin Cheng, Ju Zuo, Ying Yang, Hongru Zhao, Ling Int J Nanomedicine Original Research PURPOSE: The present study aimed to construct a co-loading platform encapsulating curcumin and paclitaxel at ratios of 2:1–80:1 (w/w) designated “CU-PTX-LNP” and explored the synergistic effects of CU-PTX at different composite proportions on liver cancer cells using the combination index (CI) method. METHODS: The CU lipid nanoplatform (CU-LNP) formulation was optimized via single-factor and orthogonal experiments. Various concentrations of PTX were added to the optimal formulation of CU-LNP to generate CU-PTX-LNP and the nanoplatform characterized via differential scanning calorimetry (DSC), transmission electron microscope (TEM), X-ray diffraction (XRD), zeta potential, polydispersity index (PDI), and size analyses. The cumulative release, stability, and cytotoxicity of CU-PTX-LNP in LO2, HepG2, and SMMC-7221 cells were assessed in vitro, followed by safety investigation and pharmacokinetic studies in vivo. The anti-tumor activity of CU-PTX-LNP was also evaluated using nude mice. RESULTS: CU-PTX-LNP formulations containing CU:PTX at a range of proportions (2:1–80:1; w/w) appeared as uniformly dispersed nanosized spherical particles with high entrapment efficiency (EE> 90%), sustained release and long-lasting stability. Data from in vitro cytotoxicity assays showed a decrease in the IC(50) value of PTX of CU-PTX-LNP (by 5.47–332.7 times in HepG2 and 4.29–143.21 times in SMMC-7221 cells) compared to free PTX. In vivo, CU-PTX-LNP displayed excellent biosafety, significant anti-tumor benefits and enhanced pharmacokinetic behavior with longer mean residence time (MRT((0-t);) CU: 4.31-fold, PTX: 4.61-fold) and half-life (t(1/2z;) CU: 1.83-fold, PTX: 2.28-fold) relative to free drugs. CONCLUSION: The newly designed CU-PTX-LNP platform may serve as a viable technological support system for the successful production of CU-PTX composite preparations. Dove 2023-04-23 /pmc/articles/PMC10135418/ /pubmed/37122500 http://dx.doi.org/10.2147/IJN.S399289 Text en © 2023 Wei et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Wei, Yuxun Wei, Yumeng Sheng, Lin Ma, Jingwen Su, Zhilian Wen, Jie Li, Lanmei Jia, Qiang Liu, Huiyang Si, Hui Xiong, Linjin Chen, Jinglin Cheng, Ju Zuo, Ying Yang, Hongru Zhao, Ling Construction of Curcumin and Paclitaxel Co-Loaded Lipid Nano Platform and Evaluation of Its Anti-Hepatoma Activity in vitro and Pharmacokinetics in vivo |
title | Construction of Curcumin and Paclitaxel Co-Loaded Lipid Nano Platform and Evaluation of Its Anti-Hepatoma Activity in vitro and Pharmacokinetics in vivo |
title_full | Construction of Curcumin and Paclitaxel Co-Loaded Lipid Nano Platform and Evaluation of Its Anti-Hepatoma Activity in vitro and Pharmacokinetics in vivo |
title_fullStr | Construction of Curcumin and Paclitaxel Co-Loaded Lipid Nano Platform and Evaluation of Its Anti-Hepatoma Activity in vitro and Pharmacokinetics in vivo |
title_full_unstemmed | Construction of Curcumin and Paclitaxel Co-Loaded Lipid Nano Platform and Evaluation of Its Anti-Hepatoma Activity in vitro and Pharmacokinetics in vivo |
title_short | Construction of Curcumin and Paclitaxel Co-Loaded Lipid Nano Platform and Evaluation of Its Anti-Hepatoma Activity in vitro and Pharmacokinetics in vivo |
title_sort | construction of curcumin and paclitaxel co-loaded lipid nano platform and evaluation of its anti-hepatoma activity in vitro and pharmacokinetics in vivo |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10135418/ https://www.ncbi.nlm.nih.gov/pubmed/37122500 http://dx.doi.org/10.2147/IJN.S399289 |
work_keys_str_mv | AT weiyuxun constructionofcurcuminandpaclitaxelcoloadedlipidnanoplatformandevaluationofitsantihepatomaactivityinvitroandpharmacokineticsinvivo AT weiyumeng constructionofcurcuminandpaclitaxelcoloadedlipidnanoplatformandevaluationofitsantihepatomaactivityinvitroandpharmacokineticsinvivo AT shenglin constructionofcurcuminandpaclitaxelcoloadedlipidnanoplatformandevaluationofitsantihepatomaactivityinvitroandpharmacokineticsinvivo AT majingwen constructionofcurcuminandpaclitaxelcoloadedlipidnanoplatformandevaluationofitsantihepatomaactivityinvitroandpharmacokineticsinvivo AT suzhilian constructionofcurcuminandpaclitaxelcoloadedlipidnanoplatformandevaluationofitsantihepatomaactivityinvitroandpharmacokineticsinvivo AT wenjie constructionofcurcuminandpaclitaxelcoloadedlipidnanoplatformandevaluationofitsantihepatomaactivityinvitroandpharmacokineticsinvivo AT lilanmei constructionofcurcuminandpaclitaxelcoloadedlipidnanoplatformandevaluationofitsantihepatomaactivityinvitroandpharmacokineticsinvivo AT jiaqiang constructionofcurcuminandpaclitaxelcoloadedlipidnanoplatformandevaluationofitsantihepatomaactivityinvitroandpharmacokineticsinvivo AT liuhuiyang constructionofcurcuminandpaclitaxelcoloadedlipidnanoplatformandevaluationofitsantihepatomaactivityinvitroandpharmacokineticsinvivo AT sihui constructionofcurcuminandpaclitaxelcoloadedlipidnanoplatformandevaluationofitsantihepatomaactivityinvitroandpharmacokineticsinvivo AT xionglinjin constructionofcurcuminandpaclitaxelcoloadedlipidnanoplatformandevaluationofitsantihepatomaactivityinvitroandpharmacokineticsinvivo AT chenjinglin constructionofcurcuminandpaclitaxelcoloadedlipidnanoplatformandevaluationofitsantihepatomaactivityinvitroandpharmacokineticsinvivo AT chengju constructionofcurcuminandpaclitaxelcoloadedlipidnanoplatformandevaluationofitsantihepatomaactivityinvitroandpharmacokineticsinvivo AT zuoying constructionofcurcuminandpaclitaxelcoloadedlipidnanoplatformandevaluationofitsantihepatomaactivityinvitroandpharmacokineticsinvivo AT yanghongru constructionofcurcuminandpaclitaxelcoloadedlipidnanoplatformandevaluationofitsantihepatomaactivityinvitroandpharmacokineticsinvivo AT zhaoling constructionofcurcuminandpaclitaxelcoloadedlipidnanoplatformandevaluationofitsantihepatomaactivityinvitroandpharmacokineticsinvivo |